TY  - JOUR
AU  - Majem, M
AU  - García-Martínez, E
AU  - Martinez, M
AU  - Muñoz-Couselo, E
AU  - Rodriguez-Abreu, D
AU  - Alvarez, R
AU  - Arance, A
AU  - Berrocal, A
AU  - de la Cruz-Merino, L
AU  - Lopez-Martin, J A
PY  - 2020
DO  - 10.1007/s12094-019-02273-x
UR  - http://hdl.handle.net/10668/15018
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed...
LA  - en
KW  - Immunotherapy
KW  - Toxicity
KW  - irAEs
KW  - Antineoplastic Agents, Immunological
KW  - Clinical Trials as Topic
KW  - Disease Management
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Humans
KW  - Immunotherapy
KW  - Medical Oncology
KW  - Neoplasms
KW  - Practice Guidelines as Topic
KW  - Societies, Medical
TI  - SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
TY  - research article
VL  - 22
ER  -